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Background: Scarce information exists regarding the preventive effect of periodontal treatment in the recurrence
of cardiovascular events. Prevention may be achieved by targeting risk factors for recurrent coronary artery disease
(CAD) in patients with previous history of cardiovascular events. The aim of this trial is to compare the effect of two
periodontal treatment approaches on levels of C-reactive protein, lipids, flow-mediated dilation and serum
concentrations of proinflammatory and endothelial markers in stable CAD patients with periodontitis over a period
of 12 months.
Methods/design: This is a randomized, parallel design, examiner blinded, controlled clinical trial. Individuals from
both genders, 35 years of age and older, with concomitant diagnosis of CAD and periodontitis will be included.
CAD will be defined as the occurrence of at least one of the following events 6 months prior to entering the trial:
documented history of myocardial infarction; surgical or percutaneous myocardial revascularization and lesion
>50% in at least one coronary artery assessed by angiography; presence of angina and positive noninvasive testing
of ischemia. Diagnosis of periodontitis will be defined using the CDC-AAP case definition (≥2 interproximal sites
with clinical attachment loss ≥6 mm and ≥1 interproximal site with probing depth ≥5 mm). Individuals will have to
present at least ten teeth present to be included. One hundred individuals will be allocated to test (intensive
periodontal treatment comprised by scaling and root planing) or control (community periodontal treatment
consisting of one session of supragingival plaque removal only) treatment groups. Full-mouth six sites per tooth
periodontal examinations and subgingival biofilm samples will be conducted at baseline, 3, 6 and 12 months after
treatment. The primary outcome of this study will be C-reactive protein changes over time. Secondary outcomes
include levels of total cholesterol, LDL-C, HDL-C, triglycerides, IL-1β, IL-6, TNFα, fibrinogen, ICAM-1, VCAM-1 and
E-selectin. These outcomes will be assessed at all time points over 12 months. Flow-mediated dilation will be
assessed at baseline, 1, 3 and 6 months after periodontal therapy.
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Discussion: This trial will provide new evidence regarding the effect of periodontal treatment on risk markers for
recurrence of cardiovascular events in stable coronary artery disease patients.
Trial registration number: ClinicalTrials.gov Identifier, NCT01609725
Keywords: Periodontal diseases, Cardiovascular diseases, C-reactive protein, Non-surgical periodontal therapy,
Coronary artery disease, Randomized controlled trial, Endothelial function, LipidsBackground
Cardiovascular diseases (CVD) are still considered the
main cause of mortality and morbidity all over the world
[1]. In the last years, efforts have been made to define
the inflammatory pathways that lead to cardiovascular
events aiming to define more effective therapeutic and
preventive strategies. In this regard, it has been demon-
strated that many proinflammatory biomarkers play an
important role in the cascade of events observed
in CVD, mainly C-reactive protein (CRP) and other
molecules such interleukins, fibrinogen and adhesion
molecules [2-4].
Periodontal diseases have been considered a probable
risk factor for CVD with a great amount of evidence
from observational studies associating the two condi-
tions [5-10]. The increase in the risk of coronary artery
disease in periodontal patients is estimated to be 24%
higher after adjusting for important confounding factors
[11]. Despite the considerable amount of evidence asso-
ciating the two conditions, there is still lack of interven-
tional studies to better elucidate the effect of periodontal
treatment on the prevention of CVD [10,12].
The biological plausibility linking periodontal diseases
to CVD is supported by the findings that periodontal in-
flammation and infection lead to an increase in blood
levels of the above-mentioned important biomarkers re-
lated to CVD. For instance, levels of CRP are higher in
periodontitis compared to healthy patients, and reduc-
tion of this marker is observed after periodontal therapy
in otherwise healthy individuals [13,14]. Interleukin 1β,
interleukin 6, fibrinogen and other proinflammatory
biomarkers have also been found in elevated levels in
healthy patients with periodontitis [15,16]. It has also
been demonstrated that periodontal disease may
negatively influence endothelial function directly or
indirectly [17-20].
Although there are some interventional studies evalu-
ating the systemic effects of periodontal therapy [14],
there is little information regarding the impact of peri-
odontal treatment on the recurrence of cardiovascular
events. Most of the studies have been conducted with
otherwise healthy patients with periodontitis, limiting
the applicability of the findings to patients suffering
from CVD. To the best of our knowledge, there are no
randomized controlled trials published to date assessingthe preventive effect of periodontal therapy in true
endpoints of cardiovascular disease, i.e., major cardio-
vascular events such as myocardial infarction and
stroke. By reviewing the literature, we were able to find
two small interventional studies showing that peri-
odontal treatment might reduce some CVD blood risk
markers. One of the studies demonstrated that CRP
and hemostatic factors improved after periodontal
treatment in a small group of 18 non-smokers with a
history of a recent CVD event [21]. Another study
evaluated hypertensive patients with periodontitis and
showed that periodontal therapy might reduce levels of
CRP and fibrinogen [22].
Recently, a study protocol of a short-term randomized
controlled trial about the effect of periodontal therapy
on endothelial function and some blood biomarkers for
CVD was published [23]. The study is planned to be
conducted with systemically healthy individuals with
periodontitis and will provide data for primary preven-
tion of CVD.
The aim of this article is to describe the protocol of a
randomized controlled trial that was designed to com-
pare the effect of intensive and community periodontal
treatments on levels of C-reactive protein, lipids,
flow-mediated dilation and serum concentrations of
proinflammatory and endothelial markers in stable
coronary artery disease patients with periodontitis over
a 12-month period.Methods/design
Study design and centers
This is a randomized, parallel design, examiner-blinded,
controlled clinical trial. This study will be conducted at
the School of Dentistry of the Federal University of
Rio Grande do Sul and at the University Hospital of
Porto Alegre in Brazil. Cardiovascular patients will be
recruited at the Ischemic Heart Disease Clinic at the
university hospital. Blood samples and laboratory ana-
lyses will be conducted at the Clinical Research Center
at the university hospital. Flow-mediated dilation will be
performed at the sector of non-invasive methods of the
university hospital. Periodontal clinical examinations
and treatments will be conducted at the Periodontal
Department of the School of Dentistry.
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Individuals from both genders, 35 years of age and older,
with concomitant diagnosis of CAD and periodontitis
will be selected for the study. The diagnosis of CAD will
be recalled from the history of acute coronary syndrome
episodes or percutaneous/surgical revascularization [24]
recorded at the hospital files. Specifically, CAD will be
defined as the occurrence of at least one of the following
events 6 months prior to entering the trial: documented
history of myocardial infarction; surgical or percutan-
eous myocardial revascularization and lesion >50% in at
least one coronary artery assessed by angiography;
presence of angina and positive noninvasive testing of
ischemia.
Diagnosis of periodontitis will be defined using the
CDC-AAP case definition [25]. Individuals will be classi-
fied as having severe chronic periodontitis in the pres-
ence of ≥2 interproximal sites with clinical attachment
loss ≥6 mm and ≥1 interproximal site with probing
depth ≥5 mm in non-adjacent teeth. Moreover, included
individuals have to present at least 12 teeth.
Individuals will be excluded from the study if they use
antibiotics or anti-inflammatory drugs during the follow-
up period of the study.Ethical considerations
All participants will read and sign an informed consent
before entering the study. The study protocol was ap-
proved by the Institutional Review Boards of the univer-
sity hospital (protocol no. 12–265) and the Federal
University of Rio Grande do Sul (protocol no. 18341).
The study will be conducted according to the principles
of the Declaration of Helsinki for human studies and
to the Brazilian legislation for human studies of the
Ministry of Health.Cardiovascular care
This study will be conducted with stable coronary artery
disease patients who will be receiving cardiovascular
care for at least 6 months at the Ischemic Heart Disease
Clinic, a tertiary care cardiovascular clinic, at the
University Hospital of Porto Alegre. Cardiovascular care
provided in this tertiary clinic includes medication and
counseling. The staff of the clinic comprises cardiolo-
gists, nurses, nutritionists and physiotherapists. The
protocol of cardiovascular care in this clinic includes
statins for the majority of the patients. When appropri-
ate, oral hypoglycemic, insulin, acetylsalicylic acid and
antihypertensive drugs are also prescribed. Counseling
includes mainly health-related lifestyle behavioral modi-
fications such as daily exercise, smoking cessation and
dietary therapy. The mean follow-up time of the patients
that attend the clinic is 5 years.Sample size
The sample size of the present trial was estimated using
a statistical software (G*Power 3 for Macintosh). The
change in serum levels of C-reactive protein was consid-
ered the main outcome for sample size estimation. It
was estimated that 42 individuals in each treatment arm
will be necessary to find reductions in C-reactive protein
of 1.5 mg/l (standard deviation = 1.5) and 0.5 mg/l
(standard deviation = 0.5) in the test and control groups,
respectively. Alpha and beta errors of 5% and 20%,
respectively, were used in the estimation. An attrition
rate of 20% is expected during the study; consequently,
50 patients in each group will be included.
Interventions
The test group (TG) will consist of intensive periodontal
treatment comprising one session of supragingival scal-
ing and personalized oral hygiene instructions, followed
by one to four sessions of subgingival scaling and root
planing (SRP) by quadrant, under local anesthesia, in a
period of 14 days. Individuals will be followed monthly
during the first 6 months and at each 3 months until the
end of the 12-month study period. In the follow-up
sessions, professional plaque removal, oral hygiene
instructions and reinforcement will be provided.
The control group (CG) will receive community
periodontal treatment similar to that provided by the
Brazilian public health system, consisting of only one
session of supragingival scaling followed by standard oral
hygiene instructions.
Treatments will be performed by two experienced
periodontists (I.W.J.R. and C.K.). Before the beginning of
the study, the two clinicians will undergo a period of
training and discussion of the therapeutic approaches
with the aim of standardization of the test and control
interventions.
Study protocol
Eligible individuals will be invited to follow the protocol
of visits described below (Figure 1):
 Visit I: application of a structured questionnaire,
general clinical evaluation, baseline periodontal
examination and subgingival microbiological
samples.
 Visit II: baseline flow-mediated dilation,
anthropometric assessment and blood samples.
 Visit III: Start of periodontal treatment according
to randomization. After this visit, periodontal
therapy will be conducted according to
randomization.
 Visit IV (30 days after the last session of periodontal
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Figure 1 Flowchart of the study participation
and examinations.
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periodontal treatment): second follow-up flow-
mediated dilation assessment, first follow-up blood
samples, periodontal clinical examination and
subgingival microbiological samples.
 Visit VI (6 months after the last session of
periodontal treatment): third follow-up flow-
mediated dilation assessment, second follow-upblood samples and periodontal clinical examination
and subgingival microbiological samples.
 Visit VII (12 months after the last session of
periodontal treatment): final follow-up blood
samples, periodontal clinical examination and
subgingival microbiological samples.
Randomization
Stratified randomization will be conducted. Individuals
will be stratified into localized or generalized periodon-
titis groups using a cutoff point of 30% of teeth with
clinical attachment loss ≥ 6 mm since the extent of
disease may be a prognostic factor for the response to
non-surgical periodontal treatment.
A specific program (randomization.com) for allocation
in test and control groups will be used by generating a
random numbers sequence. Randomization will be
conducted in blocks of 20 individuals after attributing
codes to each participant. An external assistant not in-
volved in the study will conduct randomization to war-
rant allocation concealment. Codes will be kept until the
end of analyses to maintain blindness of the examiner
and statistician.
Blood markers
Each individual will provide two 10-ml samples of blood
collected by a trained nurse from the antecubital fossa.
Fasting blood samples will be obtained between 7:00 a.
m. and 12:00 p.m. to control for possible diurnal varia-
tions. Blood samples for traditional cardiovascular blood
markers will be immediately centrifuged and analyzed.
Blood samples used for proinflammatory and endothelial
markers will be centrifuged at 4°C and 4.000 rpm for 10
min (ALC PK 120 R, ALC International, Milan, Italy).
The serum will be sampled and stored in Eppendorf
tubes at −80°C until analysis.
Traditional cardiovascular blood risk markers to be
assessed will be glucose, glycated hemoglobin, triglycer-
ides (TG), total cholesterol, and high- and low-density
lipoprotein cholesterol (HDL-C and LDL-C). The following
proinflammatory markers will be assessed: C-reactive pro-
tein, interleukin 1β (IL-1β), IL-6, tumor necrosis factor α
(TNFα) and fibrinogen. ICAM-1, VCAM-1 and E-selectin
will be the measured to assess the endothelial function.
These markers will be measured at baseline, 3, 6 and 12
months after treatment.
High-sensitive CRP, glucose, TG, total cholesterol and
HDL-C will be measured by automated enzymatic col-
orimetric methods (ADVIA 1800, Siemens, Germany)
following the manufacturer’s instructions. CRP will be
measured using the intensified immunoturbidimetry by
latex (CRP_2). Glucose will be obtained using the
glucose-hexokinase method II (GLUH). Total cholesterol
will be dosed by the colorimetric enzymatic method
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dase followed by a Trinder type endpoint. Triglycerides
will be measured by the Trinder GPO method. HDL-C
will be assessed by the HDL-Directo (HDL-D) using the
principles of elimination/catalase. LDL-C will be calcu-
lated using the Friedwald formula [LDL-C = total
cholesterol – (HDL-C + TG/5)]. Non-HDL-C will be
calculated by the subtraction of HDL-C from total chol-
esterol. Very low density lipoprotein cholesterol (VLDL-
C) will be calculated dividing TG by 5. Glycated
hemoglobin will be obtained by high-precision chroma-
tography (Merck-Hitachi L-9100, Merck, Germany).
Proinflammatory and endothelial function blood markers
will be measured using specific kits for Luminex (Milliplex
map human panels, EMD Millipore Corp., Billerica, MA,
USA).
Periodontal clinical examination
The periodontal clinical examinations will be conducted
by one single calibrated examiner to assess the peri-
odontal status of each participant. Clinical examinations
will be performed using a 10-mm round-tip manual Wil-
liams periodontal probe. All permanent teeth, excluding
the third molars, will be examined at six sites per tooth
(disto-buccal, mid-buccal, mesio-buccal, disto-palatal,
mid-palatal, mesio-palatal). Visible plaque (VP), gin-
gival recession (GR), periodontal probing depth (PD)
and bleeding on probing (BOP) will be recorded.
Clinical attachment loss will be obtained by the sum of
GR and PD.
Subgingival biofilm
The supragingival biofilm will be removed using sterile
cotton and curettes. Relative isolation will be conducted
in the area to be sampled. The subgingival biofilm sam-
ples will be obtained using no. 30 sterile paper points
inserted for 1 min in the pocket. Paper points will be
stored in one Eppendorf tube at −20°C until analyzed.
The four deepest sites of each individual will be
sampled.
The presence of periodontopathogenic bacteria in the
subgingival biofilm will be assessed by real-time poly-
merase chain reaction (RT-PCR). Three species will be
evaluated (T. forsythia, P. gingivalis and T. denticola).
Endothelial function
Non-invasive measurements of endothelial function will
be conducted by flow-mediated dilation (FMD) of the
brachial artery using bidimensional ultrasound equip-
ment. Individuals will have to be rested and will lay in a
controlled-temperature room. All vasodilation medica-
tion will have to be interrupted for at least 4 h before
the examination, if possible. Individuals will also be ad-
vised to refrain from exercising, drinking caffeine andsmoking for at least 4 h before the examination. The
examination will start after 15 min of rest in the supine
position with the arms in a comfortable position. An
image of the brachial artery will be obtained above the
antecubital fossa in a longitudinal plane. The flow will
be monitored with the Doppler positioned at a 65o angle,
and images will be obtained between the lumen and the
wall of the vein. A sphygmomanometer will be inflated
at the right forearm for 5 min, at least 50 mmHg above
the systolic pressure, for measurement of reactive
hyperemia. Images will be established 30 s before and
until 2 min after sphygmomanometer deflation, synchro-
nized with the “R” wave of the electrocardiogram. FMD
will be expresses as the relative variation of the brachial
diameter in the hyperemic phase and defined as [(post-
hyperemic diameter – baseline diameter)/baseline diam-
eter] × 100.
After 15 min of the reactive hyperemic measurement
and artery diameter normalization, the baseline artery
diameter will be measured again. In the sequence, a dose
(spray) of sublingual NTG will be administered to evalu-
ate dependent endothelial vasodilation with images ac-
quired after 5 min [26].
Demographics, behavioral and clinical variables
A structured questionnaire will be applied to all partici-
pants to obtain demographic and behavioral data. Age,
socioeconomic level, education, medication use, smoking
habits and frequency of physical activities will be
recorded. Individuals will be examined clinically to
measure height, weight and blood pressure. Body mass
index (BMI) will be calculated dividing the weight by the
square of the height.
Primary outcome
The primary outcome of the present trial will be changes
in serum concentrations of C-reactive protein.
Secondary outcomes
Secondary outcomes will include:
 Non-invasive measurements of endothelial function
(FMD);
 Traditional cardiovascular risk markers (total
cholesterol, LDL-C, HDL-C and triglycerides);
 Proinflammatory biomarkers (IL-1β, IL-6, TNFα and
fibrinogen);
 Endothelial function biomarkers (ICAM-1, VCAM-1
and E-selectin).
Independent/exposure variables and confounding
The main exposure variable will be composed by test
and control periodontal treatments. The impact of each
treatment on the primary and secondary outcomes will
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factors: age, gender, BMI, physical activity, glycated
hemoglobin, use of oral hypoglycemic drugs, smoking
exposure and subgingival microbiota.
Statistical analyses
Continuous variables will be described using means and
standard deviations or median and range in case of
asymmetric distribution of data. Categorical variables
will be presented using frequency distribution. An
intention-to-treat approach will be used in the analysis
of this trial taking into consideration all dropouts during
the follow-up period.
Univariate analyses will be conducted using chi-square
and t tests for independent samples. Multivariate models
will be fitted using generalized estimating equations to
compare changes in each outcome according to test and
control periodontal treatment groups controlling for
confounding factors. P values <0.05 will be considered
statistically significant. A statistical package (Stata 12 for
Macintosh, STATA Corp., College Station, TX, USA) will
be used. The individual will be considered the unit of
analysis.
Trial status
This is an ongoing trial. One first block of randomized
patients is receiving the interventions, and more partici-
pants are being recruited.
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